BioCryst/BCRX

$5.71

-3.69%
-
1D1W1MYTD1YMAX

About BioCryst

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers and commercializes oral, small-molecule medicines. The Company focuses on oral treatments for rare diseases, in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), BCX9930, BCX9250, PERAMIFLU (peramivir injection), galidesivir, and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. BCX9930 is an oral, potent, and selective small molecule inhibitor of Factor D. Galidesivir is a broad-spectrum antiviral that is active against viral families.

Ticker

BCRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jon Stonehouse

Employees

531

Headquarters

Durham, United States

BioCryst Metrics

BasicAdvanced
$1.19B
Market cap
-
P/E ratio
-$1.25
EPS
1.93
Beta
-
Dividend rate

What the Analysts think about BioCryst

Analyst Ratings

Majority rating from 12 analysts.
Buy

Price Targets

Average projection from 11 analysts.
142.03% upside
High $30.00
Low $6.00
$5.71
Current price
$13.82
Average price target

BioCryst Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-41.63% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$86.7M
5.22%
Net income
$-36.1M
-52.06%
Profit margin
-41.63%
-54.44%

BioCryst Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 27.05%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.28
-$0.40
-$0.19
-$0.31
-
Expected
-$0.30
-$0.23
-$0.23
-$0.24
-$0.22
Surprise
-6.3%
75.21%
-18.59%
27.05%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell BioCryst stock

Buy or sell BioCryst stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing